Fortune 500 Konnect
Home /
+1(617) 341 6100
1 877 634 8789
+44 2032 045100
+1 617-341-6992
mediainfo@vrtx.com
investorinfo@vrtx.com
vertexgrants@vrtx.com
patient_advocacy@vrtx.com

We’re moving forward with the Phase 3 development program for our investigational once-daily triple combination regimen for people with cystic fibrosis. Learn more Vertex and CRISPR Therapeutics share new clinical data on investigational potential treatments for severe sickle cell disease and transfusion-dependent beta thalassemia at the European Hematology Association (EHA) Annual Meeting Read more about how we continued to operate as a responsible business, supported our communities and drove lasting social and environmental change in 2020. A...Read more